Skip to main content
Premium Trial:

Request an Annual Quote

DxTerity, Duke Partnership Wins $10.4M BARDA Extension for Biodosimeter Development

NEW YORK (GenomeWeb) – Duke University has been awarded $10.4 million from the US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) to continue the development with DxTerity Diagnostics of a genetic test for radiation exposure.  

The funds extend the project's contract to early 2016 and bring total funding for the project to $43 million since 2009. An initial partnership between Duke, the University of Arizona, and DxTerity was established that year to develop a high-throughput, automated, direct-from-blood system for large-scale detection of RNA biomarkers indicating radiation exposure.

A molecular biodosimeter would be useful to triage patients after a nuclear disaster or mass radiation exposure since low-level exposure does not result in obvious initial symptoms, the partners said.

In a statement, DxTerity officials said the firm plans to seek US Food and Drug Administration approval of the biodosimeter within the next three years.

"If cleared, the radiation absorption test would be the first direct-from-blood, multiplex gene expression test approved by the FDA, and would open the door for other direct-from-blood gene assays," Bob Terbrueggen, DxTerity's founder and CEO said.

Rancho Dominguez, Calif.-based DxTerity received a Small Business Innovation Research contract in late 2013 to further translate its technology into a test for radiation sickness susceptibility to help manage patients undergoing cancer treatment. It continues to seek partners for its technology and recently launched a line of at-home blood collection tubes and reagent kits for multiplex PCR that use its RNA-stabilization chemistry.  

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.